To obtain information about the nature of the immunogens in the ribosomal vaccine (fraction II) of Pseudomonas aeruginosa, we studied the specificity of rabbit antibodies to fraction II. Crossed immunoelectrophoresis demonstrated the presence of antibodies which precipitated with ribosomal antigens, but not with lipopolysaccharide (LPS). By means of an enzyme-linked immunosorbent assay, antibodies to LPS were detected in antibodies to fraction II. Antibodies to fraction II could protect mice against a lethal challenge with P. aeruginosa. Absorption experiments demonstrated that the protective ability of antibodies to fraction II was due to antibodies to cell envelope antigens, whereas antibodies to ribosomal antigens did not contribute to the protection. Antibodies to LPS could be detected in mice 1 week after a single vaccination with fraction II. It was concluded that the protective activity of fraction II was due, at least in part, to the presence of LPS in the ribosomal vaccine. Treatment of fraction II with ribonuclease decreased the protective activity of the ribosomal vaccine. Addition of synthetic polyadenylic acid-polyuridylic acid restored the protective activity of ribonuclease-treated fraction II, indicating that RNA in the ribosomal vaccine might act as an adjuvant or a carrier in the presentation of the contaminating cell envelope antigens. The protective activity and the toxicity of fraction II were compared with the protective activity and the toxicity of fraction I, which contained cell envelope components, including LPS, and of purified LPS. The results indicated that protection by the ribosomal vaccine was associated with a slightly higher toxicity than was protection by fraction I, whereas purified LPS was the most toxic vaccine.
Since Youmans and Youmans showed the protective activity of ribosome-rich preparations from Mycobacterium tuberculosis (24) , effective ribosomal vaccines have been prepared from various microorganisms (6) . However, considerable controversy exists in literature concerning the immunogenic principle of these vaccines. Investigators working on ribosomal vaccines of salmonellae have variously concluded that the active moiety is ribonucleic acid (RNA) (21) , protein isolated from the ribosomal fraction (14) , 0 antigens (5), or cell surface proteins contaminating the ribosomal preparation (15) . Recently, several authors concluded that the protective activity of the ribosomal vaccines was due to contaminating cell surface components; no evidence was presented showing that the ribosomes themselves contributed to the protection (7, 12, 15) .
In a previous report, the isolation of a purified ribosomal vaccine (fraction II) and a fraction containing cell envelope components (fraction I) from Pseudomonas aeruginosa was described (8) LPS was extracted from aqueous suspensions of freeze-dried bacteria with 45% (wt/vol) phenol at 700C (9) . The combined aqueous phases were dialyzed against water and subsequently centrifuged for 4 h at 100,000 x g at 40C. The sediment was suspended in sterile water and freeze-dried. The dry material was suspended in sterile water and incubated at 370C with deoxyribonuclease (0.5 mg/ml; E. Merck AG, Darmstadt, West Germany) for 30 min.
Pancreatic RNase (0.5 mg/ml) and T1 RNase (200 U/mi) (Boehringer Mannheim Corp., Mannheim, West Germany) were added, and incubation was continued for 60 min. Subsequently, pronase E (0.5 mg/ ml; Merck) was added, and incubation was continued for 1 h. The mixture was centrifuged for 4 h at 100,000 x g at 40C, and the suspended pellet was freeze-dried. Treatment with RNase and pronase E was repeated, until the amounts of RNA and protein in the preparation were reduced to 2.4 and 8.4%, respectively. By the determination of KDO, the final preparation was estimated to contain 1,100 pg of LPS per mg (dry weight).
Rabbit antibodies against fraction I (fr. I-Ab) and fraction II (fr. IH-Ab). All rabbits were bled from the ear vein before immunization to obtain preimmune sera. Rabbits were injected intracutaneously with 3 mg of fraction I (dialyzed overnight against distilled water) or with 20 mg of fraction H. The fractions were incorporated in 1 volume of Arlacel (1.5 and 2 ml, respectively) containing 200 pg of muramyl dipeptide (Institut Pasteur Production, Paris, France). Booster injections without adjuvant were given at 4 and 5 weeks after the first injection. At 4 days after the last injection, the rabbits were bled by cardiac puncture. Groups of three to four rabbits were used for each fraction, and the immune sera of the individual rabbits in each group were pooled.
The sera were cooled in ice and diluted with 1 volume of phosphate-buffered physiological saline (PBS). Two volumes of saturated (NH4)2SO4 solution (pH 7.4) were added slowly. The mixture was stirred for 30 min at 00C and centrifuged for 10 Decomplementation was performed by heating the antibody preparation at 560C for 30 min. ,B-Mercaptoethanol treatment of decomplemented antibody preparations was performed as described by Lieberman et al. (11) .
Antisera of mice. Sera were obtained from mice by orbital puncture at 6 days after vaccination. Sera from five mice were pooled for the determination of specific antibodies.
Absorption of rabbit antibodies. Absorption of fr. I-Ab and fr. II-Ab before use in crossed immunoelectrophoresis was performed by incubation for 30 min at 370C with 1 volume of fraction I (10 mg/ml), fraction II (10 mg/ml), LPS (1 mg/ml), or living P. aeruginosa bacteria (2.5 x 109/ml). Precipitates were removed by centrifugation. After absorption with living bacteria, the antibody preparations were filtered through a 0.2-pm Sartorius filter.
Absorption of the antibody preparations before use in the enzyme-linked immunosorbent assay (ELISA) or in passive protection experiments was performed with a one-eighth dilution of decomplemented fr. I-Ab and with undiluted decomplemented fr. II-Ab. One volume of antibody preparation was incubated with 1 volume of fraction II (10 mg/ml), LPS (1, 2, or 4 mg/ ml), or killed bacteria (2.5 x 10'0/ml). Bacteria were killed by incubating 19 Crossed immunoelectrophoresis. Crossed immunoelectrophoresis was carried out on glass plates (10 by 10 cm) with a 1.1% agarose gel (Merck) in 0.1 M barbital buffer (pH 8.6) containing 0.01% Merthiolate. The thickness of the gel was 1 mm. The volume of the sample was 10 pl. The first-dimension electrophoresis was carried out at 10 V/cm for 1 h at 120C.
The second-dimension electrophoresis was carried out at 2.5 V/cm for 16 h at 120C in an agarose gel containing 0.1 ml of the antibody preparation per ml of gel. Each plate was divided in two parts, so that two samples could be run per plate. After the seconddimension electrophoresis, the gel was washed twice for 1.5 h in 0.9% NaCl and subsequently for 1 h in VOL. 31, 1981 898 GONGGRIJP ET AL. distilled water. After drying, the plates were stained with 0.5% (wt/vol) Coomassie brilliant blue G (Merck) in ethanol-glacial acetic acid-water (45:10:45) for 15 min. The excess of dye was removed by repeated washings in dye-free solvent.
ELISA. ELISA for the detection of rabbit antibodies to LPS was performed as described by Vos et al. (22) with slight modifications. Coating of the microplates was performed overnight with a final concentration of 2.5 mg of LPS per ml at room temperature. The trays were incubated with serum dilutions for 1 h at 37°C. After washing, the trays were incubated with peroxidase-labeled goat anti-rabbit immunoglobulin G (Nordic Immunological Laboratories, Tilburg, The Netherlands) in a dilution of 1:500 for 1.5 h at 37°C. The substrate 5-aminosalicylic acid was purified by recrystallization after filtration over activated charcoal. The reaction was evaluated visually and expressed as log2 of the highest dilution giving a positive reaction. The specificity of ELISA was controlled by the use of Escherichia coli LPS for the coating of the microplates.
Mouse antibodies to LPS were determined in the same way with peroxidase-labeled sheep anti-mouse immunoglobulin G (Institut Pasteur Production) in a dilution of 1:500.
Passive protection of mice with rabbit antibodies. Mice were injected intraperitoneally with 0.2 ml of serial dilutions of rabbit antibodies in PBS. After 3 h, a lethal challenge with P. aeruginosa was given intraperitoneally.
Vaccination and challenge of mice. Mice were vaccinated and challenged as described previously (8) with the following modifications. Fraction II (0.1 ml) was mixed with an equal volume of adjuvant, i.e., a sonicated suspension containing 1.5 mg of dimethyl dioctadecyl ammonium bromide (DDA) per ml of PBS; vaccinations were given intraperitoneally. The challenge dose contained 3.5 50% lethal doses of P. aeruginosa. Deaths, which occurred principally within 2 days after challenge, were recorded 7 days after challenge.
PD50. Vaccine doses that protected 50% of the mice against a challenge of 3.5 50% lethal doses (PD50) were determined graphically as described by Nowotony (17) .
Treatment of fraction II with RNase and addition of poly(A-U). Before enzymatic treatment, fraction II was dialyzed against 0.005 M ethylenediaminetetraacetic acid (pH 7.2) overnight at 4°C and then dialyzed against distilled water for 1 h. RNase A, ENZYGEL (20 mg; Boehringer Mannheim) was added to 2 mg of fraction II in a total volume of 4.5 ml. The mixture was incubated on a roller mixer for 4 h at 37°C. RNase A, ENZYGEL was removed from the mixture by centrifugation at 100 x g for 10 min and washed several times with a total volume of 15 Toxicity of vaccines to lead acetate-sensitized mice. Vaccines were dialyzed against distilled water at 4°C overnight. To dilutions of the vaccine lead acetate was added to a final concentration of 20 mg/ ml. A volume of 0.1 ml of the vaccine in lead acetate was injected intravenously in the tail vein. Deaths were recorded 7 days after injection. To inject 10 mg of fraction II per mouse, fraction II was concentrated by freeze-drying after dialysis. Lead acetate (0.1 ml) was injected 15 min before the injection of 0.1 ml of fraction 11 (100 mg/ml).
TDso. Vaccine doses that were lethal to 50% of lead acetate-sensitized mice (TD50) were determined graphically as described by Nowotony (17) .
Statistical evaluation. Significance levels for protection were determined by the Fisher exact test, as described by Bradley (4).
RESULTS
Crossed immunoelectrophoresis. Crossed immunoelectrophoresis of fractions I and II against fr. I-Ab and fr. II-Ab, respectively, resulted in different precipitation patterns ( Fig.  1A and B) . Precipitation patterns of fraction I against fr. II-Ab and of fraction II against fr. IAb demonstrated the presence of cross-reacting material in fractions I and II ( Fig. 1C and D) . fr. I-Ab contained antibodies precipitating with LPS (Fig. 1E) . No precipitation was observed when LPS was run against fr. II-Ab (Fig. 1F) . Absorption of fr. I-Ab with fraction I (5 mg/ml) resulted in the complete disappearance of the precipitation pattern of fraction I against absorbed fr. I-Ab ( Fig. 2A) . After absorption of fr. II-Ab with fraction II (5 mg/ml), only one weak precipitation line was visible when fraction II was run against absorbed fr. II-Ab (Fig. 2B) . Part of the precipitation pattern of fraction I against fr. I-Ab disappeared when fr. I-Ab were absorbed with LPS or with whole cells of P. aeruginosa ( Fig. 2C and E) . No loss of precipitation lines from the precipitation pattern of fraction II against fr. II-Ab was observed when fr. II-Ab were absorbed with LPS or with bacterial cells (Fig. 2D and F) .
Detection of antibodies to LPS by ELISA. By means of ELISA, antibodies to LPS could be detected in fr. I-Ab and in fr. II-Ab ( When the percentages of survival were plotted as a function of the corresponding titers of antibodies to LPS, it appeared that a similar correlation existed between survival and titers of antibodies to LPS induced by fraction I or LPS (Fig. 3) . The results suggested that protection by fraction II was associated with lower titers of antibodies to LPS than was protection by fraction I or LPS.
Since in fractions I and II the presence of LPS was demonstrated by the ability of the fractions to induce antibodies to LPS, it was of interest to determine whether the protective capacity of fraction I, fraction II, and LPS was correlated with the concentration of LPS in these vaccines. The PD50 values of the vaccines were calculated from the results shown in Table 4 . LPS was estimated by the determination of KDO. It appeared that the PD50 of the purified LPS vaccine contained 24 times more LPS than did the PD50 of fraction I ( Ratio of the PD50 to the TDh0 of LPS, fraction I, and fraction II. The ratio of the protective capacity of a vaccine to its toxicity has been used as a measure for its therapeutic quality (2) . The lower the PD5o/TD5o ratio, the less toxic is the vaccine dose needed to achieve a defined level of protection. The ratio of the PD5o to the TD5o for lead acetate-sensitized mice of LPS, fraction I, and fraction II is shown in Table 8 .
As judged by the PD5o/TDwo ratio, the therapeutic quality of LPS is inferior to that of fractions I and II. The PD5o/TD5o ratio of fraction II is somewhat higher than that of fraction I. (7, 15) ; no evidence was found for a function of the ribosomes in these vaccines. In contrast, a purified ribosomal vaccine (fraction II) of P. aeruginosa, of which the protective activity was destroyed by treatment of the vaccine with RNase, has been described (8) ysis (8) . In this paper, an analysis of antisera to fraction II was presented which demonstrated the presence of LPS in the ribosomal vaccine.
Crossed immunoelectrophoresis with fr. II-Ab demonstrated the presence of many different antigens in the ribosomal fraction. Some ribosomal antigens cross-reacted with antibodies to fraction I, a fraction which contained cell envelope components. Antibodies to LPS could not be detected in fr. II-Ab by crossed immunoelectrophoresis. However, antibodies to LPS were detected in fr. II-Ab by ELISA. When fr. II-Ab were absorbed with fraction II, the antibodies which precipitated with the ribosomal antigens in crossed immunoelectrophoresis disappeared (Fig. 2B) . In contrast, the titer of antibodies to LPS in fr. II-Ab was not reduced by this treatment (Table 1) . Thus, LPS was present in the ribosomal vaccine, but the amount of LPS in fraction II was not sufficient to reduce the titer of antibodies to LPS.
Mice could be protected by fr. I-Ab and fr. IIAb against a lethal challenge with P. aeruginosa. Absorption of fr. II-Ab with P. aeruginosa cells and with fraction II demonstrated that the protection by fr. II-Ab was due to antibodies to cell envelope antigens. Antibodies to ribosomal antigens did not contribute to the protection. Although it is likely that the protective activity of fr. I-Ab and fr. II-Ab is mainly due to the antibodies to LPS, it cannot be excluded that b Number of mice is given within parentheses. antibodies to other cell envelope components contributed to the protection. In this study, LPS was considered to be an indicator for the presence of cell envelope components. In mice, fraction I, fraction II, and LPS induced antibodies to LPS at 6 days after a single vaccination. Increasing doses of vaccine were INFECT. IMMUN. 'Number of mice is given within parentheses. Fig. 3 suggested that protection by fraction II was associated with lower titers of antibodies to LPS than was protection by fraction I and LPS. This might indicate that an additional protective mechanism contributed to the protective activity of fraction II. It was also observed that a high dose of poly(A * U) (300 ,ug) protected mice against a lethal challenge with P. aeruginosa ( ribosomal vaccine protected mice against a Pseudomonas infection, whereas no antibodies to LPS were detected in the sera of these animals. Thus, there are several indications that the protective activity of the ribosomal vaccine is not due only to its capacity to induce antibodies to LPS.
As the serotype-specific protection by fraction I (8) was likely due to the LPS in this fraction, it was a surprise to find a discrepancy between the concentrations of LPS in the PD50 of fraction I and in the PD50 of the purified LPS preparation (1 and 24 ng of LPS, respectively). This discrepancy might be due to the presence of different immunogens in fraction I. However, the titers of antibodies to LPS induced by fraction I and the LPS vaccine were associated with similar percentages of survival (Fig. 3) . Therefore, it is unlikely that protection induced by fraction I is primarily due to antibodies against non-LPSlike antigens. Another explanation could be that the immunogenicity of the purified LPS vaccine was decreased by the purification method. Skidmore et al. (19) and Morrison and Leive (16) have reported that several properties of LPS were affected when phenol extraction was used in comparison with milder extraction procedures.
Low toxicity has been mentioned as one of the attractive prospects of ribosomal vaccines, as these vaccines might contain low concentrations of toxic cell envelope components (10) . However, only a few investigators have determined the toxicity of their ribosomal vaccine (2) . Trial experiments have pointed out that toxic effects of the vaccines used in this study, including LPS, could be determined only when extremely high concentrations were applied. Therefore, the concentration of endotoxin in fractions I and II has been tested in lead acetate-sensitized mice since these were reported to have an increased sensitivity to the toxic effects of LPS (18) . The toxicity of non-LPS-like materials in the vaccines was considered negligible. The TD5os of the purified LPS vaccine, fraction I, and fraction II were estimated to contain 2.1, 2.9, and less than 1.6 ,ug of LPS, respectively, by an independent method for a determination of LPS. Thus, the toxicity of fraction I was in agreement with the concentration of LPS in this fraction. If the concentration of LPS in the TD50 of fraction II is near 1.6 ,ug, the toxicity of fraction II could be due to the LPS in this fraction. However, high quantities of material had to be injected intravenously to reach a toxic dose of fraction II, which might have influenced the determination of the TD50 of the ribosomal vaccine.
Whereas the concentration of LPS in the PD50 of the purified LPS vaccine was 24-fold higher than that in the PD50 of fraction I, the concentration of LPS in the TD50 of fraction I and that in the purified LPS vaccine were similar. If the former result is due to a decrease in the immunogenicity of purified LPS by the extraction method, the latter result implies that the toxicity of LPS is not decreased proportionally by the extraction. Since the toxicity of LPS is associated with the lipid A part of the molecule, whereas the carbohydrate side chains carry the serotype-specific 0 antigens, toxicity and immunogenicity may have been affected differently by the phenol extraction. Calculation of the PDso/TD5o ratio revealed that protection by fraction I was associated with the lowest toxicity for lead acetate-sensitized mice. This ratio was 2.4-fold higher for fraction II and 35-fold higher for the LPS vaccine. Thus, under these experimental conditions, protection by the ribosomal vaccine is associated with a slightly higher toxicity than is protection by fraction I. The purified LPS preparation is the most toxic vaccine. Lieberman has prepared a purified ribosomal vaccine of P. aeruginosa, peak B, which was shown to be free of LPS by the use of labeled LPS and by chemical means (10) . This vaccine induced mouse protective antibodies in rabbits (11) . The nature of the antigens to which these protective antibodies were directed was not clarified. No evidence was found that antibodies to LPS were present in the antiserum to peak B by means of a passive hemagglutination assay. However, the protection by the ribosomal vaccine, as well as the passive protection of mice by the antiserum to the ribosomal vaccine, was reported to be serotype specific (10, 11) . In view of our experience with the determination of antibodies to LPS, it is questionable whether the method used by Lieberman et al. for detecting antibodies to LPS in antiserum to peak B has been sensitive enough to exclude the presence of antibodies to LPS in this antiserum.
Different opinions have been expressed concerning the role of RNA in RNase-sensitive vaccines. Youmans and Youmans (25) The results presented in this paper confirmed the latter observations. The purified ribosomal vaccine of P. aeruginosa has the capacity to induce antibodies to LPS, and the protective activity of this vaccine is sensitive to RNase, suggesting that the ribosomes have the function of a carrier or an adjuvant in the presentation of the cell surface antigens.
